Display options
Cite
Anantha RV, Shaler CR, Meilleur CE, et al. The Future Liver Remnant in Patients Undergoing the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS) Maintains the Immunological Components of a Healthy Organ. Front Med (Lausanne). 2016;3:32doi: 10.3389/fmed.2016.00032.
Anantha, R. V., Shaler, C. R., Meilleur, C. E., Parfitt, J., Haeryfar, S. M., & Hernandez-Alejandro, R. (2016). The Future Liver Remnant in Patients Undergoing the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS) Maintains the Immunological Components of a Healthy Organ. Frontiers in medicine, 332. https://doi.org/10.3389/fmed.2016.00032
Anantha, Ram Venkatesh, et al. "The Future Liver Remnant in Patients Undergoing the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS) Maintains the Immunological Components of a Healthy Organ." Frontiers in medicine vol. 3 (2016): 32. doi: https://doi.org/10.3389/fmed.2016.00032
Anantha RV, Shaler CR, Meilleur CE, Parfitt J, Haeryfar SM, Hernandez-Alejandro R. The Future Liver Remnant in Patients Undergoing the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS) Maintains the Immunological Components of a Healthy Organ. Front Med (Lausanne). 2016 Aug 04;3:32. doi: 10.3389/fmed.2016.00032. eCollection 2016. PMID: 27556025; PMCID: PMC4972819.
Copy Download .nbib Format: NLM
Share it on

Front Med (Lausanne). 2016 Aug 04;3:32. doi: 10.3389/fmed.2016.00032. eCollection 2016.

The Future Liver Remnant in Patients Undergoing the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy (ALPPS) Maintains the Immunological Components of a Healthy Organ.

Frontiers in medicine

Ram Venkatesh Anantha, Christopher Ryan Shaler, Courtney Erin Meilleur, Jeremy Parfitt, S M Mansour Haeryfar, Roberto Hernandez-Alejandro

Affiliations

  1. Department of Surgery, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  2. Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University , London, ON , Canada.
  3. Department of Pathology, Schulich School of Medicine and Dentistry, Western University , London, ON , Canada.
  4. Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; Division of Clinical Immunology and Allergy, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  5. Department of Surgery, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; Department of Oncology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; Division of Transplantation, University of Rochester, Rochester, NY, USA.

PMID: 27556025 PMCID: PMC4972819 DOI: 10.3389/fmed.2016.00032

Abstract

BACKGROUND AND AIMS: A short-interval, two-stage approach termed associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) increases the number of patients with extensive malignant disease of the liver and a small future liver remnant (FLR) that can undergo liver resection. While this approach results in accelerated liver hypertrophy of the FLR, it remains unknown whether this phenomenon is restricted to liver parenchymal cells. In the current study, we evaluated whether ALPPS alters the immunological composition of the deportalized lobe (DL) and the FLR.

METHODS: In this prospective, single-center study, liver tissue from the DL and the FLR were collected intra-operatively from adult patients undergoing ALPPS for their liver metastases. The extent of hypertrophy of the FLR was determined by volumetric helical computed tomography. Flow cytometry and histological analyses were conducted on liver tissues to compare the frequency of several immune cell subsets, and the architecture of the liver parenchyma between both stages of ALPPS.

RESULTS: A total of 12 patients completed the study. Histologically, we observed a patchy peri-portal infiltration of lymphocytes within the DL, and a significant widening of the liver cords within the FLR. Within the DL, there was a significantly higher proportion of B cells and CD4(+) T cells as well innate-like lymphocytes, namely mucosa-associated invariant T (MAIT) cells and natural killer T (NKT) cells following ALPPS. In contrast, the frequency of all evaluated immune cell types remained relatively constant in the FLR.

CONCLUSION: Our results provide the first description of the immunological composition of the human liver following ALPPS. We show that following the ALPPS procedure, while the immune composition of the FLR remains relatively unchanged, there is a moderate increase in several immune cell populations in DL. Overall, our results support the continued utilization of the ALPPS procedure.

Keywords: ALPPS; flow cytometry; hepatectomy; immunophenotyping; liver metastases; liver regeneration

References

  1. Gastroenterology. 2001 Jan;120(1):250-60 - PubMed
  2. Surgery. 2004 Apr;135(4):404-10 - PubMed
  3. Clin Cancer Res. 2012 Mar 1;18(5):1207-13 - PubMed
  4. Nat Rev Immunol. 2009 Sep;9(9):609-17 - PubMed
  5. Surgery. 2000 May;127(5):512-9 - PubMed
  6. Gastroenterology. 2014 Aug;147(2):473-84.e2 - PubMed
  7. Surgery. 2011 May;149(5):713-24 - PubMed
  8. Ann Surg. 2012 Mar;255(3):405-14 - PubMed
  9. Hepatology. 2008 Feb;47(2):729-36 - PubMed
  10. Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 - PubMed
  11. World J Surg. 2014 Jun;38(6):1510-9 - PubMed
  12. CMAJ. 2014 Oct 21;186(15):1163-6 - PubMed
  13. J Leukoc Biol. 2002 Oct;72(4):668-76 - PubMed
  14. J Exp Biol. 2011 Oct 1;214(Pt 19):3255-68 - PubMed
  15. Ann Surg. 2003 Feb;237(2):208-17 - PubMed
  16. Eur J Surg Oncol. 2013 Nov;39(11):1230-5 - PubMed
  17. Hepatology. 2013 Apr;57(4):1654-62 - PubMed
  18. Updates Surg. 2013 Jun;65(2):141-8 - PubMed
  19. Curr Biol. 2012 Jul 10;22(13):1166-75 - PubMed
  20. Ann Surg Innov Res. 2015 Nov 02;9:11 - PubMed
  21. Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G275-82 - PubMed
  22. Br J Surg. 2001 Feb;88(2):165-75 - PubMed
  23. Ann Surg. 2008 Mar;247(3):451-5 - PubMed
  24. HPB (Oxford). 2013 Feb;15(2):91-103 - PubMed
  25. Compr Physiol. 2013 Jan;3(1):485-513 - PubMed
  26. Ann Surg. 2012 Sep;256(3):552 - PubMed
  27. Ann Surg. 2014 Nov;260(5):839-46; discussion 846-7 - PubMed
  28. Immunol Rev. 2000 Apr;174:5-20 - PubMed
  29. J Immunol. 1985 Jun;134(6):4267-75 - PubMed
  30. Br J Surg. 2007 Nov;94(11):1386-94 - PubMed
  31. J Immunol. 2014 Sep 15;193(6):3101-12 - PubMed
  32. World J Gastroenterol. 2013 Oct 21;19(39):6548-54 - PubMed
  33. Cells. 2012 Dec 13;1(4):1261-92 - PubMed
  34. Dig Dis. 2010;28(1):31-44 - PubMed
  35. Nat Med. 2013 Sep;19(9):1096-7 - PubMed
  36. Am J Surg. 2003 Mar;185(3):221-9 - PubMed
  37. Ann Surg. 2012 Sep;256(3):e9; author reply e16-9 - PubMed
  38. Surgery. 1990 May;107(5):521-7 - PubMed
  39. Surgery. 2015 Feb;157(2):194-201 - PubMed
  40. Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G969-76 - PubMed
  41. Hepatology. 2013 May;57(5):1969-79 - PubMed
  42. Ann Surg Oncol. 2009 May;16(5):1202-7 - PubMed
  43. Ann Surg. 2015 Jul;262(1):e5-9 - PubMed
  44. J Gastrointest Surg. 2013 Apr;17(4):814-21 - PubMed
  45. Crit Rev Immunol. 2002;22(1):47-103 - PubMed
  46. Cell Stem Cell. 2014 May 1;14(5):561-74 - PubMed
  47. J Hepatol. 1998 Jan;28(1):84-90 - PubMed
  48. J Immunol. 1995 Jun 15;154(12):6324-38 - PubMed

Publication Types